New ALS drug stabilizes decline with a trend toward improved strength and mobility for some

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...
MedPage Today

FDA Panel Supports Tofersen for Rare Genetic ALS

A panel of FDA advisors voted unanimously that plasma neurofilament light chain (NfL), a biomarker of neurodegeneration, is a reasonable surrogate endpoint in amyotrophic lateral sclerosis (ALS) ...
Seeking Alpha

FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS

Accelerated approval marks a scientific advancement in treatment of superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) Approval based on reduction of neurofilament, a biomarker ...
MedPage Today

Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from ...
technologynetworks

New Drug Delays Symptom Progression in ALS

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline of neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...
Seeking Alpha

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe 1 With QALSODY, Biogen has advanced the role of neurofilament in the ...